Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company focused on universal-RAS/RAF cancer medicines, will participate in the Piper Sandler 36th Annual Healthcare Conference in New York City from December 3-5, 2024. The company's management team will present in a fireside chat format on December 5 from 1:00-1:25 pm ET, discussing their pipeline, platform, and business strategy. The presentation will be available via live webcast and archived on Immuneering's website in the Investor Relations section.
Immuneering (Nasdaq: IMRX), una compagnia oncologica in fase clinica focalizzata su farmaci universali contro il cancro RAS/RAF, parteciperà alla 36a Conferenza Sanitaria Annuale di Piper Sandler a New York dal 3 al 5 dicembre 2024. Il team di gestione dell'azienda presenterà in un formato di chat informale il 5 dicembre dalle 13:00 alle 13:25 ET, discutendo del loro pipeline, della piattaforma e della strategia aziendale. La presentazione sarà disponibile tramite webcast live e archiviata sul sito web di Immuneering nella sezione Relazioni con gli Investitori.
Immuneering (Nasdaq: IMRX), una empresa oncológica en etapa clínica centrada en medicamentos universales contra el cáncer RAS/RAF, participará en la 36ª Conferencia Anual de Salud de Piper Sandler en la ciudad de Nueva York del 3 al 5 de diciembre de 2024. El equipo de dirección de la empresa presentará en un formato de charla junto al fuego el 5 de diciembre de 1:00 a 1:25 p. m. ET, discutiendo su pipeline, plataforma y estrategia empresarial. La presentación estará disponible a través de una transmisión en vivo y se archivará en el sitio web de Immuneering en la sección de Relaciones con Inversores.
Immuneering (Nasdaq: IMRX)은 보편적인 RAS/RAF 암 치료제에 집중하는 임상 단계의 종양학 회사로, 2024년 12월 3일부터 5일까지 뉴욕에서 열리는 Piper Sandler 제36회 연례 건강 관리 회의에 참여합니다. 회사의 경영진은 12월 5일 동부 표준시 기준으로 오후 1시부터 1시 25분까지 화상 대화 형식으로 발표하며, 파이프라인, 플랫폼 및 비즈니스 전략에 대해 논의할 예정입니다. 프레젠테이션은 실시간 웹캐스트를 통해 이용 가능하며, Immuneering의 투자자 관계 섹션에서 아카이브됩니다.
Immuneering (Nasdaq: IMRX), une société d'oncologie en phase clinique axée sur les médicaments anticancéreux universels RAS/RAF, participera à la 36e Conférence Annuelle sur la Santé de Piper Sandler à New York du 3 au 5 décembre 2024. L'équipe de direction de l'entreprise présentera lors d'une discussion informelle le 5 décembre de 13h00 à 13h25 ET, abordant leur pipeline, plateforme et stratégie d'entreprise. La présentation sera disponible en direct par webcast et archivée sur le site Web d'Immuneering dans la section Relations Investisseurs.
Immuneering (Nasdaq: IMRX), ein klinisch tätiges Unternehmen in der Onkologie, das sich auf universelle RAS/RAF-Krebsmedikamente konzentriert, wird an der 36. Annual Healthcare Conference von Piper Sandler in New York City vom 3. bis 5. Dezember 2024 teilnehmen. Das Management-Team des Unternehmens wird am 5. Dezember von 13:00 bis 13:25 Uhr ET in einem informellen Gesprächsformat über ihre Pipeline, Plattform und Geschäftsstrategie präsentieren. Die Präsentation wird als Live-Übertragung verfügbar sein und im Bereich Investor Relations auf der Website von Immuneering archiviert werden.
- None.
- None.
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: December 5 from 1:00 pm – 1:25 pm ET
The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 2a trial in patients with advanced solid tumors including those harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When is Immuneering (IMRX) presenting at the Piper Sandler Healthcare Conference 2024?
Where can I watch Immuneering's (IMRX) Piper Sandler Conference presentation?
What will Immuneering (IMRX) discuss at the Piper Sandler Healthcare Conference?
Where is the Piper Sandler Healthcare Conference 2024 being held?
